Akeso's Breakthrough Drugs Secure Inclusion in China's NRDL, Enhancing Patient Treatment Options Akeso, Inc. announces the successful inclusion of five innovative drugs in China's National Reimbursement Drug List, improving treatment availability for patients.

Akeso's Breakthrough Drugs Secure Inclusion in China's NRDL, Enhancing Patient Treatment Options #China #Hong_Kong #Akeso #Ivonescimab #Ebronucimab

China NMPA Approves Ebronucimab Injection for Hypercholesterolemia Treatment

📩 info@dengyuemed.com
🔗https://dengyuemed.com

#Ebronucimab #PCSK9Inhibitor #CholesterolTreatment #NMPAApproval #ChineseBiologics #Hypercholesterolemia #CardiovascularHealth #KangrongDongfang